FGI Surges 114% as 500% EPS Revision Signals Turnaround in Consumer Cyclicals
FGI Industries Ltd led today's movers with a 114.5% gain after its EPS next-year growth projection was revised to 500%, suggesting a dramatic turnaround in profitability expectations. Skillz and Xcel Brands followed with 55.7% and 55.6% gains respectively, while Healthcare names DARE and Agilon posted 51.9% and 50.9% advances, indicating broad-based re-rating in beaten-down small-cap sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FGI | Consumer Cyclical | 2026-04-13 | N/A | +114.5% |
| SKLZ | Communication Services | 2026-04-12 | +1.0pp | +55.7% |
| XELB | Consumer Cyclical | 2026-04-10 | N/A | +55.6% |
| DARE | Healthcare | 2026-04-10 | N/A | +51.9% |
| AGL | Healthcare | 2026-04-10 | +0.0pp | +50.9% |
FGI — FGI Industries Ltd
FGI Industries Ltd triggered our screener on April 13 when analysts revised its EPS next-year growth projection to 500%, a signal that earnings expectations had fundamentally shifted. The stock has since exploded from $3.85 to $8.26, a 114.5% move that far exceeded the magnitude of the revision itself. Such outsized price action suggests the market had been pricing in distress-level valuations that no longer reflected the company's improving fundamentals. Without recent news to attribute the move to, the re-rating appears driven entirely by the consensus earnings outlook upgrade, indicating institutional accumulation on the improving narrative.
View screener snapshot from 2026-04-13 →SKLZ — Skillz Inc
Skillz Inc gained 55.7% from $2.46 to $3.83 after a modest but meaningful EPS revision from 34.9% to 35.8% growth next year. The sensitivity to a 1 percentage point revision signals extreme positioning pressure, likely with significant short interest that got squeezed when the earnings trajectory improved. Communication Services names have been under pressure, so any stabilization in the EPS outlook likely triggered covering activity. The move from $2.46 to $3.83 represents a re-rating that the market priced as confirmation that Skillz's path to profitability remains intact.
View screener snapshot from 2026-04-12 →XELB — Xcel Brands Inc
Xcel Brands Inc climbed 55.6% from $1.33 to $2.07 following a 64.2% EPS next-year growth revision that caught our screener on April 10. The Consumer Cyclical sector has seen selective rotation into names with improving earnings visibility, and XELB's sharp re-rating reflects that dynamic. At $1.33, the stock appears to have been priced for failure rather than the turnaround scenario that analyst estimates now paint. The 64.2% growth projection revision validated the bull case and attracted buying that pushed the stock toward $2.07 in under two weeks.
View screener snapshot from 2026-04-10 →DARE — Dare Bioscience Inc
Dare Bioscience Inc jumped 51.9% from $1.85 to $2.81 after our April 10 detection of a 51.2% EPS next-year growth revision. Healthcare biotech and specialty pharma names have experienced volatile trading as the market reassesses development-stage companies' paths to commercialization. The 51.2% earnings growth revision signals that analysts now see improved monetization potential, likely for DARE's women's health pipeline. The 51.9% price gain tracks closely with the revision magnitude, suggesting efficient market repricing of the company's near-term earnings power.
View screener snapshot from 2026-04-10 →AGL — Agilon Health Inc
Agilon Health Inc posted a 50.9% gain from $20.46 to $30.88 despite a flat EPS revision at 25.1% growth, an anomaly that points to sector rotation rather than earnings-specific catalysts. Healthcare services names have benefited from defensive positioning as growth sectors rotate, and Agilon's value-based care model appears to have attracted that flow. The stock was likely oversold heading into mid-April, making it susceptible to a sharp technical rebound when broader market sentiment shifted. The disconnect between unchanged EPS estimates and a 50.9% price move indicates the market was pricing in a fear premium that has now unwound.
View screener snapshot from 2026-04-10 →Today's movers reveal a market willing to aggressively re-rate small-cap names with improving earnings visibility, particularly in Consumer Cyclicals and Healthcare. The FGI and XELB moves demonstrate that extreme undervaluation can unwind rapidly once consensus estimates shift, while AGL's surge despite flat estimates highlights sector rotation dynamics driving outsized moves independent of earnings revisions.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →